Association between Nonalcoholic Fatty Liver Disease at CT and Coronary Microvascular Dysfunction at Myocardial Perfusion PET/CT.
Journal
Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pubmed:
6
3
2019
medline:
31
1
2020
entrez:
6
3
2019
Statut:
ppublish
Résumé
Background Cardiovascular disease is a major cause of mortality in patients with nonalcoholic fatty liver disease (NAFLD). However, the association of NAFLD with coronary microvascular dysfunction is, to our knowledge, unknown. Purpose To determine whether coronary microvascular dysfunction is more prevalent in patients with NAFLD and to determine whether coronary microvascular dysfunction predicts major adverse cardiac events (MACE) independently of NAFLD. Materials and Methods This retrospective study (2006-2014) included patients without evidence of obstructive epicardial coronary artery disease and healthy left ventricular ejection fraction (≥40%) at a clinical rest and stress myocardial perfusion PET/CT. NAFLD was defined by a mean hepatic attenuation of less than 40 HU at CT and coronary microvascular dysfunction as a coronary flow reserve (CFR) of less than 2.0. A composite of all-cause mortality, myocardial infarction, coronary revascularization, and hospitalization because of heart failure comprised MACE (130 of 886 patients; 14.7%). The relation between NAFLD and MACE was assessed by using multivariable Cox regression analysis. Results Among 886 patients (mean age, 62 years ± 12 [standard deviation]; 631 women [mean age, 62 years ± 12 years] and 255 men [mean age, 61 years ± 12]; and ejection fraction, 63% ± 9), 125 patients (14.1%) had NAFLD and 411 patients (46.4%) had coronary microvascular dysfunction. Coronary microvascular dysfunction was more prevalent (64.8% vs 43.4%;
Identifiants
pubmed: 30835188
doi: 10.1148/radiol.2019181793
pmc: PMC6492883
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
330-337Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL135438
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002542
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Ann Intern Med. 1993 Jan 15;118(2):81-90
pubmed: 8416322
Ann Intern Med. 2005 Nov 15;143(10):722-8
pubmed: 16287793
Atherosclerosis. 2010 Jul;211(1):182-6
pubmed: 20181335
Menopause. 2015 Dec;22(12):1323-7
pubmed: 26154274
Diabetes. 2005 Dec;54(12):3541-6
pubmed: 16306373
J Am Coll Cardiol. 2011 Aug 9;58(7):740-8
pubmed: 21816311
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
J Hepatol. 2016 Sep;65(3):589-600
pubmed: 27212244
AJR Am J Roentgenol. 2010 Mar;194(3):623-8
pubmed: 20173137
N Engl J Med. 1996 Apr 11;334(15):952-7
pubmed: 8596596
Radiology. 2015 Mar;274(3):693-701
pubmed: 25369449
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Am J Gastroenterol. 2008 Dec;103(12):3029-35
pubmed: 18853970
Gut. 2017 Feb;66(2):323-329
pubmed: 27599521
Int J Cardiovasc Imaging. 2016 Jun;32 Suppl 1:73-82
pubmed: 26831056
Gut. 2017 Jun;66(6):1138-1153
pubmed: 28314735
World J Gastroenterol. 2015 Jun 14;21(22):6820-34
pubmed: 26078558
Dig Liver Dis. 2016 Dec;48(12):1410-1417
pubmed: 27697419
Circulation. 2011 Nov 15;124(20):2215-24
pubmed: 22007073
BMJ. 2011 Nov 18;343:d6891
pubmed: 22102439
Circulation. 2017 Dec 12;136(24):2325-2336
pubmed: 28864442
N Engl J Med. 2005 Apr 21;352(16):1685-95
pubmed: 15843671
J Hepatol. 2018 May;68(5):1018-1024
pubmed: 29274406
JACC Cardiovasc Imaging. 2017 Sep;10(9):1016-1027
pubmed: 28330662
Semin Nucl Med. 2014 Sep;44(5):344-57
pubmed: 25234079
Am J Physiol Endocrinol Metab. 2006 Aug;291(2):E282-90
pubmed: 16478772
J Nucl Med. 2009 Jul;50(7):1062-71
pubmed: 19525467
Sci Rep. 2016 Sep 16;6:33386
pubmed: 27633274